Novo Nordisk is suing Eli Lilly over allegedly deceptive weight-loss drug ads, claiming they mislead consumers by comparing high-dose GLP-1 drugs to lower doses of Novo’s meds—hidden in tiny print. As scrutiny mounts on pharmaceutical advertising and competition in the booming GLP-1 market intensifies with new oral drugs, Novo’s legal move could reshape how these ads are regulated and perceived.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
